TEL AVIV, Israel and BETHESDA, Maryland, June 26, 2018 -- /D.M.O. Newswire/ -- Cannabics Pharmaceuticals Inc. (OTC:CNBX), a leader in personalized cannabis medicine focused on cancer and its side effects, announced today that senior members of its scientific team will be attending the International Cannabinoid Research Society conference, to be held in Leiden, the Netherlands July 1st – 4th 2018, and will be available for one on one meetings.
The International Cannabinoid Research Society, ICRS, a non-political organization, is dedicated to scientific research in all fields of cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system. It also acts as a source for impartial information on Medical Cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research.
In attendance will be Dr Haleli Sharir, Dr Nir Kfir, and Dr. Eyal Ballan, the company's Co-Founder and CTO.
Dr. Sharir is reknown for her role in possibly identifying a new cannabinoid receptor, GPR55. As a member of a research group, it was observed that human GPR55 can be activated by several types of cannabinoids. The research was funded by the National Institute of Health (NIH/NIDA), and results are available through the National Center for Biotechnology Information (NCBI).
Dr. Kfir's background is in molecular genetics, specializing in RNA processing and chromatin organization. In previous work, he focused on high throughput screening and on researching new chemotherapy treatments that restore a cancer cell's ability to undergo "programmed cell death".
Eyal Ballan, CTO of Cannabics Pharmaceuticals said "We look forward to interacting and meeting with fellow enthusiastic researchers who share our vision and are looking to introduce cannabinoids into mainstream medicine. Following the recent FDA's approval of a cannabinoid based drug we see great potential in bringing legitimacy to the medical cannabis industry that will lead to many additional approvals".
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a United States-based public company that is developing cannabinoid diagnostic tests for the personalized treatment of cancer. Cannabics is developing a blood test that allows practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient's profile and cancer. Cannabics' approach can also be used to develop cannabinoid-based therapies as preventive or primary cancer treatments – not just palliative, the way it's being used now. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the mainstream of cancer therapies. The company's R&D is based in Israel, where it is licensed to conduct scientific and clinical research on harnessing the therapeutic properties of cannabinoid formulations. For more information, please visit www.cannabics.com.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on April 6th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.